Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti‐factor IXa/factor X bispecific antibody emicizumab

Essentials The activated partial prothrombin time (aPTT) cannot predict the activity of emicizumab (Emi). Adjusted clot waveform analyses using a prothrombin time (PT)/aPTT initiator were developed. Activity of Emi in the co‐presence of factor VIII or bypassing agents was quantified. This assay is useful for assessing coagulation potential in Emi‐treated hemophilia A.

[1]  F. Rosendaal,et al.  Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review , 2018, Journal of thrombosis and haemostasis : JTH.

[2]  Y. Abe,et al.  An Evaluation of Hemostatic Abnormalities in Patients With Hemophilia According to the Activated Partial Thromboplastin Time Waveform , 2018, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[3]  H. Wada,et al.  Emicizumab Prophylaxis in Hemophilia A with Inhibitors. , 2017, The New England journal of medicine.

[4]  Tetsuji Sato,et al.  Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. , 2017, Blood advances.

[5]  K. Nogami,et al.  Clot waveform analysis using CS‐2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  J. Oldenburg,et al.  Emicizumab Prophylaxis in Hemophilia A with Inhibitors , 2017, The New England journal of medicine.

[7]  K. Nogami,et al.  Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens , 2017, Thrombosis and Haemostasis.

[8]  B. Ewenstein,et al.  Pro‐ and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA® in prophylactic therapy , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  Tetsuji Sato,et al.  Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. , 2016, The New England journal of medicine.

[10]  K. Yoneyama,et al.  A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. , 2016, Blood.

[11]  K. Nogami,et al.  Phenotypic Heterogeneity of Hemostasis in Severe Hemophilia , 2015, Seminars in Thrombosis & Hemostasis.

[12]  K. Nogami,et al.  Optimal monitoring of bypass therapy in hemophilia A patients with inhibitors by the use of clot waveform analysis , 2014, Journal of thrombosis and haemostasis : JTH.

[13]  M. Shima,et al.  Anti‐factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation , 2014, Journal of thrombosis and haemostasis : JTH.

[14]  J. Thachil,et al.  Towards standardization of clot waveform analysis and recommendations for its clinical applications , 2013, Journal of thrombosis and haemostasis : JTH.

[15]  K. Nogami,et al.  The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X. , 2013, Thrombosis and haemostasis.

[16]  T. Igawa,et al.  Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity , 2013, PloS one.

[17]  C. Witmer,et al.  Factor VIII inhibitors in hemophilia A: rationale and latest evidence , 2013, Therapeutic advances in hematology.

[18]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  Tsukasa Suzuki,et al.  A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model , 2012, Nature Medicine.

[20]  M. Trossaërt,et al.  Prevalence, biological phenotype and genotype in moderate/mild hemophilia A with discrepancy between one‐stage and chromogenic factor VIII activity , 2011, Journal of thrombosis and haemostasis : JTH.

[21]  J. G. van der Bom,et al.  The long-term course of factor VIII inhibitors in patients with congenital haemophilia A without immune tolerance induction. , 2010, Thrombosis and haemostasis.

[22]  H. M. van den Berg,et al.  A survey of adherence to haemophilia therapy in six European countries: results and recommendations , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  Tomoko Matsumoto,et al.  New assays for monitoring haemophilia treatment , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[24]  D. Monroe.  Further understanding of recombinant activated factor VII mode of action. , 2008, Seminars in hematology.

[25]  C. Lee,et al.  Parents of children with haemophilia – a transforming experience , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[26]  A. Giles,et al.  The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay , 2006, Journal of thrombosis and haemostasis : JTH.

[27]  Maureane Hoffman,et al.  Remodeling the Blood Coagulation Cascade , 2003, Journal of Thrombosis and Thrombolysis.

[28]  A. Giles,et al.  The Utility of activated Partial Thromboplastin Time (aPTT) Clot Waveform Analysis in the Investigation of Hemophilia A Patients with very Low Levels of Factor VIII Activity (FVIII:C) , 2002, Thrombosis and Haemostasis.

[29]  A. Stead,et al.  Properties of Optical Data from Activated Partial Thromboplastin Time and Prothrombin Time Assays , 1997, Thrombosis and Haemostasis.

[30]  A. Satterfield,et al.  TREATMENT , 1924, California and western medicine.